Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
2021 · The Lancet Haematology · 61 citations
https://doi.org/10.1016/s2352-3026(21)00333-1
H
Hiroshi Ureshino
Saga University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
192
Papers
838
Citations
15
h-index
22
i10-index
Hiroshi Ureshino is an academic researcher from Saga University. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Acute Myeloid Leukemia Research & Chronic Lymphocytic Leukemia Research. The author has an h-index of 15, co-authored 164 publications.
ORCID: 0000-0002-5034-3699Papers by this author
worksKIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study
2024 · Blood Neoplasia · 7 citations
https://doi.org/10.1016/j.bneo.2024.100001
Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman
2021 · Cureus · 6 citations
https://doi.org/10.7759/cureus.17942
Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute
2024 · Blood Cells Molecules and Diseases · 1 citations
https://doi.org/10.1016/j.bcmd.2024.102870
Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report
2024 · Annals of Hematology · 1 citations
https://doi.org/10.1007/s00277-024-06153-5
(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation
2025 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-025-98534-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat